Even after anti-androgen therapy, docetaxel remains useful in prostate cancer
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent ...
Jan 11, 2016
0
1